stockrow
Saturday 7 November 2026
Export LENZ’s income statement to Excel — free account
LENZ Therapeutics, Inc.
LENZ Healthcare Biotechnology
LENZ Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $19.1 million.
- Revenue
- −72.9%
- EPS
- −67.1%
- Free cash flow
- −147.2%
Quarter to September 2026, against a year earlier
3.47
0.46
+15.28%
Follow LENZ
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
9.76 | 8.30 | 13.67 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.41) | (4.60) | (8.54) | (13.96) | |
P/B ratio |
0.63 | 0.81 | 1.16 | 1.62 | |
Price to Tangible BV |
0.63 | 0.81 | 1.16 | 1.62 | |
EV/Sales |
(6.02) | (1.84) | 1.46 | 0.00 | |
EV/EBITDA |
0.50 | 0.29 | 0.00 | 0.00 | |
EV/Operating CF |
0.58 | 0.35 | (0.35) | (2.47) | |
EV/FCF |
0.58 | 0.35 | (0.35) | (2.44) | |
Quick Ratio |
11.17 | 12.81 | 10.03 | 13.81 | |
Current Ratio |
11.66 | 13.55 | 10.40 | 14.23 | |
Net Debt/EBITDA |
6.01 | 6.46 | 5.87 | 7.62 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.06 | 0.09 | 0.09 | 0.00 | |
Operating CF/Net income |
0.72 | 1.21 | 0.81 | 0.92 | |
Capex/Depreciation |
0.00 | (0.15) | (0.16) | (0.36) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
1,059.34% | 717.79% | 2,365.07% | 2,495.78% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
122.16% | 81.52% | 227.20% | 231.61% | |
Graham Net Nets |
1.57 | 1.21 | 0.84 | 0.61 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(116.81%) | (72.01%) | (39.34%) | (17.56%) | |
Free Cash Flow Yield |
(105.84%) | (64.21%) | (30.48%) | (15.18%) | |
Revenue per Share |
0.11 | 0.17 | 0.06 | 0.06 | |
Operating CF per Share |
(0.71) | (1.23) | (1.07) | (1.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.71) | (1.23) | (1.07) | (1.15) | |
Cash per Share |
6.28 | 7.01 | 8.24 | 10.15 | |
Shareholders Equity per Share |
6.11 | 6.99 | 7.86 | 9.87 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.11 | 6.99 | 7.86 | 9.87 | |
Free Cash Flow |
(22.31) | (38.73) | (33.60) | (33.06) | |
Working Capital |
189.15 | 216.07 | 242.56 | 280.23 | |
Capital Expenditures |
0.00 | (0.02) | (0.02) | (0.04) | |
Net Current Asset Value |
189.15 | 215.95 | 242.32 | 279.88 | |
EV/EBIT |
0.50 | 0.29 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
4.92 | 4.75 | 7.30 | 4.21 | |
Average Inventory |
2.85 | — | — | — | |
Average Assets |
210.23 | 226.96 | 236.89 | 260.59 | |
Average Common Equity |
192.96 | 212.81 | 219.25 | 244.21 |
Columns are period end dates · fundamentals updated 5 Nov 2026